Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice

Cancer Immunology, Immunotherapy

Volumn 60, Issue 5, 2011, Pages 671-683

  Amos, Sally M ^a   Pegram, Hollie J ^a   Westwood, Jennifer A ^a   John, Liza B ^a   Devaud, Christel ^a   Clarke, Chris J ^a   Restifo, Nicholas P ^b   Smyth, Mark J ^a,c,d   Darcy, Phillip K ^a,c,d   Kershaw, Michael H ^a,c,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

Adjuvant; Adoptive immunotherapy; Immunotherapy; Pmel; Toll like receptor; Tumor immunology

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; CPG OLIGODEOXYNUCLEOTIDE 1826; GAMMA INTERFERON; GLYCOPROTEIN GP 100; GLYCOPROTEIN GP 100[25-33]; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 9; UNCLASSIFIED DRUG;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CONTROL; CANCER SURVIVAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; HOST CELL; IMMUNOGENICITY; KNOCKOUT MOUSE; LYMPHOCYTE TRANSFER; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SAFETY; SUBCUTANEOUS MELANOMA; T LYMPHOCYTE ACTIVATION; TUMOR ESCAPE;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL LINE, TUMOR; DENDRITIC CELLS; FLOW CYTOMETRY; IMMUNOTHERAPY, ADOPTIVE; INFLAMMATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OLIGODEOXYRIBONUCLEOTIDES; POLY I-C; T-LYMPHOCYTES; TOLL-LIKE RECEPTORS;

EID: 79955533553     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-0984-8     Document Type: Article

References (53)

1. SA Rosenberg P Spiess R Lafreniere 1986 A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes Science 233 1318 1321 3489291 10.1126/science.3489291 1:STN:280:DyaL28zhsFygsQ%3D%3D (Pubitemid 16002234)
2. ME Dudley SA Rosenberg 2003 Adoptive-cell-transfer therapy for the treatment of patients with cancer Nat Rev Cancer 3 666 675 12951585 10.1038/nrc1167 1:CAS:528:DC%2BD3sXmvVWlu7s%3D (Pubitemid 37328821)
3. AK Field AA Tytell GP Lampson MR Hilleman 1967 Inducers of interferon and host resistance. II. Multistranded synthetic polynucleotide complexes Proc Natl Acad Sci USA 58 1004 1010 5233831 10.1073/pnas.58.3.1004 1:CAS:528: DyaF2sXltFGltLs%3D
4. AM Krieg AK Yi S Matson TJ Waldschmidt GA Bishop R Teasdale GA Koretzky DM Klinman 1995 CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 546 549 7700380 10.1038/374546a0 1:CAS:528:DyaK2MXkvVKqtr8%3D
5. JA Westwood PK Darcy PM Guru J Sharkey HJ Pegram SM Amos MJ Smyth MH Kershaw 2010 Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice J Transl Med 8 42 20426873 10.1186/1479-5876-8-42
6. ME Dudley JC Yang R Sherry MS Hughes R Royal U Kammula PF Robbins J Huang DE Citrin SF Leitman J Wunderlich NP Restifo, et al. 2008 Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens J Clin Oncol 26 5233 5239 18809613 10.1200/JCO.2008.16.5449 1:CAS:528:DC%2BD1cXhsVyqsrbO
7. ME Dudley JR Wunderlich PF Robbins JC Yang P Hwu DJ Schwartzentruber SL Topalian R Sherry NP Restifo AM Hubicki MR Robinson M Raffeld, et al. 2002 Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes Science 298 850 854 12242449 10.1126/science.1076514 1:CAS:528:DC%2BD38XotFSntbY%3D (Pubitemid 35231542)
8. DJ Schwartzentruber 2001 Guidelines for the safe administration of high-dose interleukin-2 J Immunother 24 287 293 11565830 10.1097/00002371- 200107000-00004 1:CAS:528:DC%2BD3MXntFGntrY%3D (Pubitemid 32825860)
9. R Medzhitov 2001 Toll-like receptors and innate immunity Nat Rev Immunol 1 135 145 11905821 10.1038/35100529 1:CAS:528:DC%2BD38XlvF2qu74%3D (Pubitemid 33741967)
10. T Kawai S Akira 2008 Toll-like receptor, RIG-I-like receptor signaling Ann N Y Acad Sci 1143 1 20 19076341 10.1196/annals.1443.020 1:CAS:528: DC%2BD1MXpvFKrsQ%3D%3D
11. M Fukata AS Vamadevan MT Abreu 2009 Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders Semin Immunol 21 242 253 19748439 10.1016/j.smim.2009.06.005 1:CAS:528:DC%2BD1MXhtFajtrfL
12. C Pasare R Medzhitov 2005 Toll-like receptors: linking innate and adaptive immunity Adv Exp Med Biol 560 11 18 15932016 10.1007/0-387-24180-9-2 1:CAS:528:DC%2BD2MXhtlCjsLzE
13. CC Huang KE Duffy LR San Mateo BY Amegadzie RT Sarisky ML Mbow 2006 A pathway analysis of poly(I:C)-induced global gene expression change in human peripheral blood mononuclear cells Physiol Genomics 26 125 133 16554548 10.1152/physiolgenomics.00002.2006 (Pubitemid 44061321)
14. S Klaschik I Gursel DM Klinman 2007 CpG-mediated changes in gene expression in murine spleen cells identified by microarray analysis Mol Immunol 44 1095 1104 16930709 10.1016/j.molimm.2006.07.283 1:CAS:528: DC%2BD28XpvVOgs7s%3D (Pubitemid 44415981)
15. G Napolitani A Rinaldi F Bertoni F Sallusto A Lanzavecchia 2005 Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells Nat Immunol 6 769 776 15995707 10.1038/ni1223 1:CAS:528:DC%2BD2MXmtlSisLs%3D (Pubitemid 43090462)
16. D Tross L Petrenko S Klaschik Q Zhu DM Klinman 2009 Global changes in gene expression and synergistic interactions induced by TLR9 and TLR3 Mol Immunol 46 2557 2564 19535142 10.1016/j.molimm.2009.05.011 1:CAS:528: DC%2BD1MXos1Omurg%3D
17. ML Salem AN Kadima DJ Cole WE Gillanders 2005 Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity J Immunother 28 220 228 15838378 10.1097/01.cji.0000156828.75196.0d 1:CAS:528:DC%2BD2MXjtlKlu7o%3D (Pubitemid 40593987)
18. ML Salem CM Diaz-Montero AA Al-Khami SA El-Naggar O Naga AJ Montero A Khafagy DJ Cole 2009 Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C) J Immunol 182 2030 2040 19201856 10.4049/jimmunol.0801829 1:CAS:528:DC%2BD1MXhsFKkurg%3D
19. J Kohlmeyer M Cron J Landsberg T Bald M Renn S Mikus S Bondong D Wikasari E Gaffal G Hartmann T Tuting 2009 Complete regression of advanced primary and metastatic mouse melanomas following combination chemoimmunotherapy Cancer Res 69 6265 6274 19622767 10.1158/0008-5472.CAN-09-0579 1:CAS:528: DC%2BD1MXpt1Cgurw%3D
20. J Vollmer AM Krieg 2009 Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv Drug Deliv Rev 61 195 204 19211030 10.1016/j.addr.2008.12.008 1:CAS:528:DC%2BD1MXjtFKltb4%3D
21. B Huang J Zhao H Li KL He Y Chen SH Chen L Mayer JC Unkeless H Xiong 2005 Toll-like receptors on tumor cells facilitate evasion of immune surveillance Cancer Res 65 5009 5014 15958541 10.1158/0008-5472.CAN-05-0784 1:CAS:528:DC%2BD2MXltFemtLo%3D (Pubitemid 40827306)
22. C Farina M Krumbholz T Giese G Hartmann F Aloisi E Meinl 2005 Preferential expression and function of Toll-like receptor 3 in human astrocytes J Neuroimmunol 159 12 19 15652398 10.1016/j.jneuroim.2004.09.009 1:CAS:528:DC%2BD2MXisl2rtQ%3D%3D (Pubitemid 40126172)
23. G Pedersen L Andresen MW Matthiessen J Rask-Madsen J Brynskov 2005 Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium Clin Exp Immunol 141 298 306 15996194 10.1111/j.1365-2249.2005.02848.x 1:CAS:528:DC%2BD2MXotFaktbY%3D (Pubitemid 41003354)
24. V Hornung S Rothenfusser S Britsch A Krug B Jahrsdorfer T Giese S Endres G Hartmann 2002 Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides J Immunol 168 4531 4537 11970999 1:CAS:528: DC%2BD38Xjt12jt7k%3D (Pubitemid 34441357)
25. M Muzio D Bosisio N Polentarutti G D'Amico A Stoppacciaro R Mancinelli C van't Veer G Penton-Rol LP Ruco P Allavena A Mantovani 2000 Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells J Immunol 164 5998 6004 10820283 1:CAS:528:DC%2BD3cXjslemtbY%3D (Pubitemid 30389848)
26. SE Finkelstein DM Heimann CA Klebanoff PA Antony L Gattinoni CS Hinrichs LN Hwang DC Palmer PJ Spiess DR Surman C Wrzesiniski Z Yu, et al. 2004 Bedside to bench and back again: how animal models are guiding the development of new immunotherapies for cancer J Leukoc Biol 76 333 337 15155774 10.1189/jlb.0304120 1:CAS:528:DC%2BD2cXmtlKrs7s%3D (Pubitemid 39006946)
27. WW Overwijk MR Theoret SE Finkelstein DR Surman LA de Jong FA Vyth-Dreese TA Dellemijn PA Antony PJ Spiess DC Palmer DM Heimann CA Klebanoff, et al. 2003 Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8 + T cells J Exp Med 198 569 580 12925674 10.1084/jem.20030590 1:CAS:528:DC%2BD3sXms1WisL4%3D (Pubitemid 37040391)
28. KT Brunner J Mauel JC Cerottini B Chapuis 1968 Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs Immunology 14 181 196 4966657 1:CAS:528:DyaF1cXhtVens7o%3D
29. CW Hendrix JB Margolick BG Petty RB Markham L Nerhood H Farzadegan PO Ts'o PS Lietman 1993 Biologic effects after a single dose of poly(I):poly(C12U) in healthy volunteers Antimicrob Agents Chemother 37 429 435 7681656 1:CAS:528:DyaK3sXhvVejsbY%3D (Pubitemid 23072584)
30. MA Hofmann C Kors H Audring P Walden W Sterry U Trefzer 2008 Phase 1 evaluation of intralesionally injected TLR9-agonist PF-3512676 in patients with basal cell carcinoma or metastatic melanoma J Immunother 31 520 527 18463532 10.1097/CJI.0b013e318174a4df 1:CAS:528:DC%2BD1cXmsFyrs7c%3D
31. RA Robinson VT DeVita HB Levy S Baron SP Hubbard AS Levine 1976 A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors J Natl Cancer Inst 57 599 602 978771 1:STN:280:DyaE2s%2FjtFOmuw%3D%3D
32. BK Link ZK Ballas D Weisdorf JE Wooldridge AD Bossler M Shannon WL Rasmussen AM Krieg GJ Weiner 2006 Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion demonstrates immunologic modulation in patients with previously treated non-Hodgkin lymphoma J Immunother 29 558 568 16971811 10.1097/01.cji.0000211304.60126.8f 1:CAS:528:DC%2BD28XpsVantb8%3D (Pubitemid 44395280)
33. BG Molenkamp BJ Sluijter PA van Leeuwen SJ Santegoets S Meijer PG Wijnands JB Haanen AJ van den Eertwegh RJ Scheper TD de Gruijl 2008 Local administration of PF-3512676 CpG-B instigates tumor-specific CD8 + T-cell reactivity in melanoma patients Clin Cancer Res 14 4532 4542 18628468 10.1158/1078-0432.CCR-07-4711 1:CAS:528:DC%2BD1cXosFGitLk%3D
34. S Sharma CP Karakousis H Takita K Shin SP Brooks 2003 Intra-tumoral injection of CpG results in the inhibition of tumor growth in murine Colon-26 and B-16 tumors Biotechnol Lett 25 149 153 12882291 10.1023/A:1021927621813 1:CAS:528:DC%2BD3sXitlKksbc%3D (Pubitemid 36189361)
35. M Pashenkov G Goess C Wagner M Hormann T Jandl A Moser CM Britten J Smolle S Koller C Mauch I Tantcheva-Poor S Grabbe, et al. 2006 Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma J Clin Oncol 24 5716 5724 17179105 10.1200/JCO.2006.07.9129 1:CAS:528:DC%2BD2sXhtVChsL8%3D (Pubitemid 46631314)
36. JD Brody WZ Ai DK Czerwinski JA Torchia M Levy RH Advani YH Kim RT Hoppe SJ Knox LK Shin I Wapnir RJ Tibshirani, et al. 2010 In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study J Clin Oncol 28 4324 4332 20697067 10.1200/JCO.2010.28.9793
37. N Garbi B Arnold S Gordon GJ Hammerling R Ganss 2004 CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction J Immunol 172 5861 5869 15128765 1:CAS:528:DC%2BD2cXjs1Ojt74%3D (Pubitemid 38621184)
38. G Verdeil K Marquardt CD Surh LA Sherman 2008 Adjuvants targeting innate and adaptive immunity synergize to enhance tumor immunotherapy Proc Natl Acad Sci USA 105 16683 16688 18936481 10.1073/pnas.0805054105 1:CAS:528: DC%2BD1cXhtleks77O
39. Y Lou G Wang G Lizee GJ Kim SE Finkelstein C Feng NP Restifo P Hwu 2004 Dendritic cells strongly boost the antitumor activity of adoptively transferred T cells in vivo Cancer Res 64 6783 6790 15374997 10.1158/0008-5472.CAN-04-1621 1:CAS:528:DC%2BD2cXnsFOksLg%3D (Pubitemid 39297942)
40. S Gasperini M Marchi F Calzetti C Laudanna L Vicentini H Olsen M Murphy F Liao J Farber MA Cassatella 1999 Gene expression and production of the monokine induced by IFN-gamma (MIG), IFN-inducible T cell alpha chemoattractant (I-TAC), and IFN-gamma-inducible protein-10 (IP-10) chemokines by human neutrophils J Immunol 162 4928 4937 10202039 1:CAS:528:DyaK1MXisFOlsLk%3D (Pubitemid 29314899)
41. DD Taub AR Lloyd K Conlon JM Wang JR Ortaldo A Harada K Matsushima DJ Kelvin JJ Oppenheim 1993 Recombinant human interferon-inducible protein 10 is a chemoattractant for human monocytes and T lymphocytes and promotes T cell adhesion to endothelial cells J Exp Med 177 1809 1814 8496693 10.1084/jem.177.6.1809 1:CAS:528:DyaK3sXitFWisLc%3D (Pubitemid 23146150)
42. M Inngjerdingen B Damaj AA Maghazachi 2001 Expression and regulation of chemokine receptors in human natural killer cells Blood 97 367 375 11154210 10.1182/blood.V97.2.367 1:CAS:528:DC%2BD3MXlvF2jsg%3D%3D (Pubitemid 32060319)
43. M Yoneyama T Fujita 2009 RNA recognition and signal transduction by RIG-I-like receptors Immunol Rev 227 54 65 19120475 10.1111/j.1600-065X.2008. 00727.x 1:CAS:528:DC%2BD1MXhsFGls7zO
44. H Kumar S Koyama KJ Ishii T Kawai S Akira 2008 Cutting edge: cooperation of IPS-1- and TRIF-dependent pathways in poly IC-enhanced antibody production and cytotoxic T cell responses J Immunol 180 683 687 18178804 1:CAS:528:DC%2BD1cXhsVyjsA%3D%3D
45. B Seliger U Wollscheid F Momburg T Blankenstein C Huber 2001 Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells Cancer Res 61 1095 1099 11221838 1:CAS:528: DC%2BD3MXhsFSqsrY%3D (Pubitemid 32174430)
46. AS Dighe E Richards LJ Old RD Schreiber 1994 Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFN gamma receptors Immunity 1 447 456 7895156 10.1016/1074-7613(94)90087-6 1:CAS:528:DyaK2cXmt1yntro%3D (Pubitemid 2142268)
47. MK Sgagias C Nieroda JR Yannelli KH Cowan DN Danforth Jr 1996 Upregulation of DF3, in association with ICAM-1 and MHC class II by IFN-gamma in short-term human mammary carcinoma cell cultures Cancer Biother Radiopharm 11 177 185 10851535 10.1089/cbr.1996.11.177 1:CAS:528:DyaK28XkvFWhu78%3D (Pubitemid 26279399)
48. E Ersvaer J Skavland E Ulvestad BT Gjertsen O Bruserud 2007 Effects of interferon gamma on native human acute myelogenous leukaemia cells Cancer Immunol Immunother 56 13 24 16612597 10.1007/s00262-006-0159-1 1:CAS:528:DC%2BD28Xht1elsb3K (Pubitemid 44812443)
49. SE Dovhey NS Ghosh KL Wright 2000 Loss of interferon-gamma inducibility of TAP1 and LMP2 in a renal cell carcinoma cell line Cancer Res 60 5789 5796 11059775 1:CAS:528:DC%2BD3cXnvVSnt74%3D
50. CA Klebanoff Z Yu LN Hwang DC Palmer L Gattinoni NP Restifo 2009 Programming tumor-reactive effector memory CD8 + T cells in vitro obviates the requirement for in vivo vaccination Blood 114 1776 1783 19561320 10.1182/blood-2008-12-192419 1:CAS:528:DC%2BD1MXhtFWgsbbI
51. RE Miller J Jones T Le J Whitmore N Boiani B Gliniak DH Lynch 2002 4-1BB-specific monoclonal antibody promotes the generation of tumor-specific immune responses by direct activation of CD8 T cells in a CD40-dependent manner J Immunol 169 1792 1800 12165501 1:CAS:528:DC%2BD38XmtFejsrc%3D (Pubitemid 34857639)
52. AJ Korman KS Peggs JP Allison 2006 Checkpoint blockade in cancer immunotherapy Adv Immunol 90 297 339 16730267 10.1016/S0065-2776(06)90008-X 1:CAS:528:DC%2BD1cXhsVCju74%3D (Pubitemid 43765802)
53. OC Farokhzad J Cheng BA Teply I Sherifi S Jon PW Kantoff JP Richie R Langer 2006 Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo Proc Natl Acad Sci USA 103 6315 6320 16606824 10.1073/pnas.0601755103 1:CAS:528:DC%2BD28XktFamsbk%3D